Casma Therapeutics

Casma Therapeutics is a biotechnology company founded in 2018 and headquartered in Cambridge, Massachusetts, developing targeted therapies that engage the lysosomal and autophagy systems to selectively degrade disease-causing elements. The company's proprietary PHLYT platform reprograms the autophagy pathway to permanently eliminate disease targets inside cells, including aggregated proteins, damaged organelles, and pathogens. Casma's pipeline is focused on neurodegeneration, lysosomal storage disorders, liver disease, muscle disorders, and cancer, with lead program CSM-101 advancing toward development candidate nomination.